**COE Learning Network: Racial Disparities in Treating Substance Use Disorder**

**Presenter: Latonya Latamore, PhD, MS; Alexis Waksmunski, MPIA**

**Date and Time: 6/15/22- 12:00 Noon to 1:15 pm**

**Location:**Virtual Training (on Zoom)

**Host:**University of Pittsburgh, School of Pharmacy, Program and Evaluation Unit (PERU)

**Target Audience: Centers of Excellence Leadership and Staff**

**Training Objectives:**

* Examine the impact of racism and stigma on healthcare
* Locate resources for culturally sensitive care
* Implement strategies that can address racism within the COE setting

**Agenda:**

1. Welcome/ Introduction/ Objectives
2. Definitions and Foundational Principles
	1. Covert Racism
	2. Explicit Racism
	3. Implicit Bias
	4. Implicit Bias Affects Client Health Outcomes
3. Racial Disparities in Substance Use Disorder Treatment
	1. Racial Disparities
	2. Racial Disparities in OUD Treatment for Women
	3. Medications for Opioid Use Disorder (MOUD)
	4. Access and the Role of Providers
	5. Racial Disparities and Medications for OUD
	6. Impact of Racial Disparities in SUD Treatment
	7. Structural Disparities and Institutional Racism
	8. Waivered Buprenorphine Prescribers
4. Strategies and Next Steps to Address Racial Disparities in SUD Treatment
	1. Strategies and Next Steps
	2. Trauma-Informed Care and Collaboration with Peer Support
	3. Impacts of Trauma-Informed Care
	4. Decrease Stigma Related to Recovery and Medications
	5. Self-Assess MOUD Prescribing Practices and Treatment
	6. Support Providers of Color and Equitable Hiring Practices
	7. Create a Safe Environment and Accept People’s Experiences
5. Discussion/ Questions
6. Please consider any questions you have and be ready to share them with us during the discussion portion. You will be prompted to unmute yourself at that time. Until then please use the chat and mute yourself if not speaking

**Questions**

1. Black Americans are:
	1. More likely to receive MOUD treatment than their White counterparts.
	2. **Less likely to receive MOUD treatment than their White counterparts.**
	3. Just as likely to receive MOUD treatment than their White counterparts.
2. Some ways to reduce stigma include:
	1. Educating providers about substance use disorder and the effects of stigma along with the evidence behind treatment and medications.
	2. Speak out when stigmatizing language is used and avoid using it also.
	3. Listen without holding judgment and treat everyone with dignity and respect.
	4. **All the above**
3. Some things that lead to actions that create racial disparities in healthcare settings include:
	1. Implicit or unconscious bias
	2. discrimination
	3. prejudice
	4. subtle, explicit, and structural racism
	5. **All the above**
4. True or **False:** Subtle racism and implicit bias are the same things.
5. **True** or False: Implicit bias has a significant impact on client-provider relationships and interactions.

**References**

1. Barboza, G. E., & Angulski, K. (2020). A descriptive study of racial and ethnic differences of drug overdoses and Naloxone Administration in Pennsylvania. International Journal of Drug Policy, 78, 102718. https://doi.org/10.1016/j.drugpo.2020.102718

2. Cruz, T. M., & Smith, S. A. (2021). Health Equity Beyond Data: Health Care Worker Perceptions of Race, Ethnicity, and Language Data Collection in Electronic Health Records. Medical Care, 59(5), 379–385. https://doi.org/10.1097/mlr.0000000000001507

3. Duerme, R., Dorsinville, A., McIntosh-Beckles, N., & Wright-Woolcock, S. (2021). Rationale for the design and implementation of interventions addressing institutional racism at a local public health department. Ethnicity & Disease, 31(Suppl), 365–374. https://doi.org/10.18865/ed.31.s1.365

4. Entress, R. M. (2021). The intersection of race and opioid use disorder treatment: A quantitative analysis. Journal of Substance Abuse Treatment, 108589. https://doi.org/10.1016/j.jsat.2021.108589

5. Fish, J., & Syed, M. (2020). Racism, discrimination, and prejudice. The Encyclopedia of Child and Adolescent Development, 1–12. https://doi.org/10.1002/9781119171492.wecad464

6. Goldstein, E., Benton, S. F., & Barrett, B. (2020). Health risk behaviors and resilience among low-income, Black Primary Care Patients. Family & Community Health, 43(3), 187–199. https://doi.org/10.1097/fch.0000000000000260

7. Hall, W. J., Chapman, M. V., Lee, K. M., Merino, Y. M., Thomas, T. W., Payne, B. K., Eng, E., Day, S. H., & Coyne-Beasley, T. (2015). Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: A systematic review. American Journal of Public Health, 105(12), 2588–2588. https://doi.org/10.2105/ajph.2015.302903a

8. Hollander, M. A. G., Chang, C.-C. H., Douaihy, A. B., Hulsey, E., & Donohue, J.M. (2021). Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use. Drug and Alcohol Dependence, 227, 108927. https://doi.org/10.1016/j.drugalcdep.2021.108927

9. Johnson, N. L., Choi, S., & Herrera, C.-N. (2021). Black clients in expansion states who used opioids were more likely to access medication for opioid use disorder after ACA implementation. Journal of Substance Abuse Treatment, 108533. https://doi.org/10.1016/j.jsat.2021.108533

10. Lagisetty, P. A., Ross, R., Bohnert, A., Clay, M., & Maust, D. T. (2019). Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry, 76(9), 979. https://doi.org/10.1001/jamapsychiatry.2019.0876

11. Madden, E. F., Prevedel, S., Light, T., & Sulzer, S. H. (2021). Intervention stigma toward medications for opioid use disorder: A systematic review. Substance Use & Misuse, 56(14), 2181–2201. https://doi.org/10.1080/10826084.2021.1975749

12. Madden, E. F., & Qeadan, F. (2019). Racial inequities in U.S. naloxone prescriptions. Substance Abuse, 41(2), 232–244. https://doi.org/10.1080/08897077.2019.1686721

13. Manning, V., Kelly, P. J., & Baker, A. L. (2020). The role of peer support and mutual aid in reducing harm from alcohol, drugs and tobacco in 2020. Addictive Behaviors, 109, 106480. https://doi.org/10.1016/j.addbeh.2020.106480

14. Nguemeni Tiako, M. J. (2021). Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid covid-19. Journal of Substance Abuse Treatment, 122, 108214. https://doi.org/10.1016/j.jsat.2020.108214

15. Parlier-Ahmad, A. B., Pugh, M., & Martin, C. E. (2021). Treatment outcomes among black adults receiving medication for opioid use disorder. Journal of Racial and Ethnic Health Disparities. https://doi.org/10.1007/s40615-021-01095-4

16. Peeler, M., Gupta, M., Melvin, P., Bryant, A. S., Diop, H., Iverson, R., Callaghan, K., Wachman, E. M., Singh, R., Houghton, M., Greenfield, S. F., & Schiff, D. M. (2020). Racial and ethnic disparities in maternal and infant outcomes among opioid-exposed mother–infant dyads in Massachusetts (2017–2019). American Journal of Public Health, 110(12), 1828–1836. https://doi.org/10.2105/ajph.2020.305888

17. Robbins, M., Haroz, R., Mazzarelli, A., Clements, D., Jones, C. W., & Salzman, M. (2021). Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study. Journal of Substance Abuse Treatment, 130, 108405. https://doi.org/10.1016/j.jsat.2021.108405

18. Rosales, R., Janssen, T., Yermash, J., Yap, K. R., Ball, E. L., Hartzler, B., Garner, B. R., & Becker, S. J. (2021). Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19. Journal of Substance Abuse Treatment, 108648. https://doi.org/10.1016/j.jsat.2021.108648

19. Rübig, L. L., Fuchshuber, J., Köldorfer, P., Rinner, A., Fink, A., & Unterrainer, H.-F. (2021). Attachment and therapeutic alliance in substance use disorders: Initial findings for treatment in the therapeutic community. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.730876

20. Sahker, E., Pro, G., Sakata, M., & Furukawa, T. A. (2020). Substance use improvement depends on race/ethnicity: Outpatient treatment disparities observed in a large US national sample. Drug and Alcohol Dependence, 213, 108087. https://doi.org/10.1016/j.drugalcdep.2020.108087

21. Schuler, M. S., Dick, A. W., & Stein, B. D. (2021). Growing racial/ethnic disparities in buprenorphine distribution in the United States, 2007-2017. Drug and Alcohol Dependence, 223, 108710. https://doi.org/10.1016/j.drugalcdep.2021.108710

22. Simon, R., Snow, R., & Wakeman, S. (2019). Understanding why patients with substance use disorders leave the hospital against medical advice: A qualitative study. Substance Abuse, 41(4), 519–525. https://doi.org/10.1080/08897077.2019.1671942

23. Stahler, G. J., Mennis, J., & Baron, D. A. (2021). Racial/ethnic disparities in the use of medications for opioid use disorder (MOUD) and their effects on residential drug treatment outcomes in the US. Drug and Alcohol Dependence, 226, 108849. https://doi.org/10.1016/j.drugalcdep.2021.108849

24. Substance Abuse and Mental Health Services Administration. (2014). SAMSHA’s concept of trauma and guidance for a trauma-informed approach. HHS Publication No. (SMA) 14-4884. https://ncsacw.samhsa.gov/userfiles/files/SAMHSA\_Trauma.pdf,

25. Thomas, B., & Booth-McCoy, A. N. (2020). Blackface, implicit bias, and the informal curriculum: Shaping the healthcare workforce, and improving health. Journal of the National Medical Association, 112(5), 533–540. https://doi.org/10.1016/j.jnma.2020.05.012

26. Vilsaint, C. (2022, January). Using Recovery Science to Dismantle Racial Health Inequities in Opioid Use Disorder. Recovery Science Series Webinars Hosted by the Recovery Research Institute. https://www.youtube.com/watch?v=SH\_Ycv9GUmc

27. Zwick, J., Appleseth, H., & Arndt, S. (2020). Stigma: How it affects the substance use disorder patient. Substance Abuse Treatment, Prevention, and Policy, 15(1). https://doi.org/10.1186/s13011-020-00288-0